© Beta Bionics, 2019

Logos png-39.png
  • fb
  • tw
  • ig
  • in
  • yt

Caution - THE iLet IS AN INVESTIGATIONAL DEVICE, LIMITED BY FEDERAL LAW TO INVESTIGATIONAL USE

Press Releases

July 17, 2019

ConvaTec’s Unomedical subsidiary and Beta Bionics have entered into a collaboration and development agreement that will make portions of Unomedical’s world-class infusion sets available for use with the iLet Bionic Pancreas System.

January 08, 2019

Beta Bionics announces that the company has now completed its Series B equity financing, which has reached a total of $63 million.  

October 09, 2018

Beta Bionics has been awarded up to $2 million in the form of an SBIR grant (R44-DK120234) by the NIDDK, which is part of the U.S. National Institutes of Health (NIH).

Zealand Pharma and Beta Bionics announce a positive outcome from the Phase 2a clinical safety trial using dasiglucagon in the dual-hormone artificial pancreas system, developed at Boston University and licensed to Beta Bionics. 

Please reload